EyePoint (EYPT) sets DURAVYU Phase 3 DME start for Q1 2026

EyePoint Pharmaceuticals (EYPT) filed an 8-K noting two updates.

Rhea-AI Filing Summary

EyePoint Pharmaceuticals (EYPT) filed an 8-K noting two updates. The company posted an investor presentation that includes estimated cash and investments as of September 30, 2025. These figures were calculated before review by the independent registered public accounting firm and are subject to change upon completion of the quarterly report for the period ended September 30, 2025.

EyePoint also announced details for its pivotal Phase 3 program evaluating DURAVYU (vorolanib intravitreal insert) for diabetic macular edema, with first patient dosing anticipated in Q1 2026. The press release and presentation were made available on the company’s website.

Insights

Biopharma clinical/regulatory analyst

Phase 3 timing disclosed; cash figures preliminary.

EyePoint outlined a pivotal Phase 3 program for DURAVYU in diabetic macular edema, with Q1 2026 targeted for first patient dosing. A pivotal study aims to generate data suitable for regulatory submissions, so the start timing signals program progression.

The investor presentation includes estimated cash and investments as of September 30, 2025, explicitly noted as subject to change pending quarterly review. Without audited figures or additional detail in the excerpt, the disclosure primarily informs timing and administrative updates.

8-K Event Classification

3 items: 2.02, 8.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What did EyePoint Pharmaceuticals (EYPT) announce in the 8-K?

It posted an investor presentation with estimated cash and investments as of September 30, 2025 and outlined a pivotal Phase 3 DURAVYU program.

When is first patient dosing for DURAVYU’s Phase 3 DME study expected?

EyePoint anticipates first patient dosing in Q1 2026.

Are the cash and investment figures final for EYPT?

No. They are preliminary and subject to change after completion of the quarterly review for the period ended September 30, 2025.

Where can I access EyePoint’s press release and presentation?

Both were posted on the company’s website; the press release and investor presentation are also included as exhibits.

What is DURAVYU (vorolanib intravitreal insert)?

It is EyePoint’s product candidate being evaluated in a pivotal Phase 3 program for diabetic macular edema.

Which ticker and exchange does EyePoint trade on?

EyePoint trades under EYPT on The Nasdaq Global Market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/14/2025 - 04:08 PM Learn about SEC filing dates

false 0001314102 0001314102 2025-10-14 2025-10-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 14, 2025

EyePoint Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		000-51122		26-2774444
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

480 Pleasant Street
Watertown, Massachusetts		02472
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 926-5000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001		EYPT		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On October 14, 2025, EyePoint Pharmaceuticals, Inc. (the “Company”) posted an updated investor presentation (the “Presentation”) on its website at www.eyepointpharma.com which included estimated cash and investments on hand as of September 30, 2025 and certain other corporate updates. The amounts included in the presentation were calculated prior to the completion of a review by the Company’s independent registered public accounting firm and are therefore subject to change upon completion of the Company’s quarterly report for the period ended September 30, 2025. Additional information and disclosures would be required for a more complete understanding of the Company’s financial position and results of operations as of September 30, 2025.

Item 8.01 Other Events.

On October 14, 2025, the Company issued a press release announcing details for its pivotal Phase 3 program evaluating DURAVYU^™ (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME) with first patient dosing anticipated in Q1 2026. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

On October 14, 2025, the Company posted the Presentation on its website at www.eyepointpharma.com. A copy of the Presentation is filed herewith as Exhibit 99.2 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release of EyePoint Pharmaceuticals, Inc., dated October 14, 2025
99.2		Investor Presentation of EyePoint Pharmaceuticals, Inc. dated October 14, 2025
104		Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						EYEPOINT PHARMACEUTICALS, INC.
Date: October 14, 2025				By:		/s/ George O. Elston
						George O. Elston Executive Vice President and Chief Financial Officer